Literature DB >> 28921323

Effects of reduction of carrier gas flow rate on sevoflurane and isoflurane consumption and costs.

Satoru Tanaka1, Hideaki Tsuchida1, Hajime Sonoda2, Akiyoshi Namiki1.   

Abstract

PURPOSE: To evaluate whether sevoflurane and isoflurane consumption would be actually halved by halving the carrier gas flow rate, as predicted by a theoretical model, we measured the consumed volume of liquid sevoflurane and isoflurane and total costs of anesthetic gas at carrier gas flow rates of 3 and 61·min-1.
METHODS: Eighty patients of ASA physical status I or II were randomly assigned to one of four groups: sevoflurane at 3 or 61·min-1 and isoflurane at 3 or 61·min-1. Anesthesia was induced with thiamylal and maintained with sevoflurane or isoflurane, as well as with nitrous oxide in oxygen. The consumption of sevoflurane and isoflurane was measured by weighing the bottle of liquid agent, which was greater in the groups receiving 61·min-1 gas than in those receiving 31·min-1.
RESULTS: Halving the carrier gas flow rate reduced the consumption of sevoflurane by 41.8% and that of isoflurane by 52.6%. It also reduced the total cost by 44.3% for sevoflurane and 49.2% for isoflurane.
CONCLUSION: Halving the carrier gas flow rates halved the consumption of isoflurane but not of sevoflurane, indicating that factors other than carrier gas flow rates are involved in determining consumption in the clinical setting.

Entities:  

Keywords:  Anesthetic cost; Carrier gas flow; Isoflurane; Sevoflurane

Year:  1998        PMID: 28921323     DOI: 10.1007/BF02480757

Source DB:  PubMed          Journal:  J Anesth        ISSN: 0913-8668            Impact factor:   2.078


  11 in total

1.  Minimum alveolar concentrations (MAC) of isoflurande with and without nitrous oxide in patients of various ages.

Authors:  W C Stevens; W M Dolan; R T Gibbons; A White; E I Eger; R D Miller; R H DeJong; R M Elashoff
Journal:  Anesthesiology       Date:  1975-02       Impact factor: 7.892

2.  Low-flow anaesthesia. Practice, cost implications and acceptability.

Authors:  S M Cotter; A J Petros; C J Doré; N D Barber; D C White
Journal:  Anaesthesia       Date:  1991-12       Impact factor: 6.955

3.  The safety of sevoflurane has not been adequately established.

Authors:  E I Eger; J L Martin; J H Tinker
Journal:  Anesth Analg       Date:  1996-02       Impact factor: 5.108

4.  Comparing the costs of inhaled anesthetics.

Authors:  R B Weiskopf; E I Eger
Journal:  Anesthesiology       Date:  1993-12       Impact factor: 7.892

5.  MAC of sevoflurane in humans and the New Zealand white rabbit.

Authors:  M S Scheller; L J Saidman; B L Partridge
Journal:  Can J Anaesth       Date:  1988-03       Impact factor: 5.063

6.  Clonidine and lidocaine inhibition of isoflurane-induced tachycardia in humans.

Authors:  S Tanaka; H Tsuchida; H Namba; A Namiki
Journal:  Anesthesiology       Date:  1994-12       Impact factor: 7.892

7.  Cost comparison: a desflurane- versus a propofol-based general anesthetic technique.

Authors:  M K Rosenberg; P Bridge; M Brown
Journal:  Anesth Analg       Date:  1994-11       Impact factor: 5.108

8.  Increases in hemodynamic variables and catecholamine levels after rapid increase in isoflurane concentration.

Authors:  A Yli-Hankala; T Randell; T Seppälä; L Lindgren
Journal:  Anesthesiology       Date:  1993-02       Impact factor: 7.892

9.  Neurocirculatory responses to sevoflurane in humans. A comparison to desflurane.

Authors:  T J Ebert; M Muzi; C W Lopatka
Journal:  Anesthesiology       Date:  1995-07       Impact factor: 7.892

10.  The effects of sevoflurane, isoflurane, halothane, and enflurane on hemodynamic responses during an inhaled induction of anesthesia via a mask in humans.

Authors:  S Tanaka; H Tsuchida; K Nakabayashi; S Seki; A Namiki
Journal:  Anesth Analg       Date:  1996-04       Impact factor: 5.108

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.